Quality of Life in Patients with Chronic Hepatitis C Submitted to Treatment with Interferon and Ribavirin
American Journal of Nursing Science
Volume 7, Issue 3-1, June 2018, Pages: 77-85
Received: Dec. 4, 2017;
Accepted: Dec. 6, 2017;
Published: Dec. 25, 2017
Views 1369 Downloads 63
Andriana Theodorakopoulou, Hemodynamic Laboratory, Hippokration General Hospital, Athens, Greece
Maria Kapella, Director of Nursing, Hippokration General Hospital, Athens, Greece
Vasiliki Kontou, Department of Nursing Specialities, Hippokration General Hospital, Athens, Greece
Sofia Giovaso, Hemodynamic Laboratory, Onassis Cardiac Surgery Center, Athens, Greece
Theodoros Katsaras, Psychiatric Department, Sotiria Hospital, Athens, Greece
Spilios Manolakopoulos, 2nd Department of Medicine, Medical School of Athens, National and Kapodistrian University of Athens, Hippokration General Hospital, Greece
Dimitris Pectasidis, 2nd Department of Medicine, Medical School of Athens, National and Kapodistrian University of Athens, Hippokration General Hospital, Greece
John Koskinas, 2nd Department of Medicine, Medical School of Athens, National and Kapodistrian University of Athens, Hippokration General Hospital, Greece
Introduction: Chronic hepatitis C is a serious public health problem worldwide. Approximately eighty percent of the patients with acute infection will fall back to chronicity with long term complications such as cirrhosis, liver failure, hepatocellular cancer and death. The HCV infection per se has been found to be related with a variety of neuropsychiatric symptoms. Treatment of hepatitis C with interferon plus ribavirin is related with many side effects and affects the quality of patients’ life. Purpose: The purpose of this study is to assess the quality of life in patients with chronic hepatitis C undergoing treatment with interferon and Ribavirin. Data and Methodology: The research sample was 173 patients with hepatitis C who were treated in the Outpatient Liver Unit, 2nd Department of Internal Medicine, Medical School of Athens, Hippokratio General Hospital". The data were hand- collected after the Short Form 36 scale completion by the patients. For the data analysis the statistical package SPSS 13 was used and more specifically statistical t-test and anova analysis. Results: Out of all the patients participated in the study the 28.9% were women and 71.1% were men with an average age of 54.4 years with a standard deviation of 8.14 years. The 87.3% had concomitant diseases; 88.4% diabetes, 56.6% hypertension and 59.5% high cholesterol. 38.15% of the sample had re-admitted to the hospital, 18.40% had previous heart attack and 63.16% were former smokers. The statistical analysis indicated those who had a higher education degree peported higher quality of life sores in the dimensions of mental health (p=0.001), physical function (p=0.01) and vitality (p=0.000). Similar, married patients reported higher quality of life scoers in several dimension as well as patients without readmissions, patients without comorbidities and non-smokers. Conclusions: treatment with interferon and Ribavirin affects the quality of life of patients with chronic hepatitis C. Factors such as age, lifestyle, educational level, the reintroduction in the hospital and marital status can affect the life and mental health of the patient. The factors that adversely affect the quality of life must be identified and treated promptly by health professionals
Quality of Life in Patients with Chronic Hepatitis C Submitted to Treatment with Interferon and Ribavirin, American Journal of Nursing Science. Special Issue: Nursing Education and Research.
Vol. 7, No. 3-1,
2018, pp. 77-85.
Perz ZF, Farrington LA, Pecoraro C, Hutin YJF, Armstrong GL. Estimaned global prevalence of hepatitis C virus infection. 42nd Annual Meet-ing of the Infectious Diseases Society of America: Boston, MA, USA: Sept 30- Oct 3, 2004.
Gogos CA, FoukaKP, Nikiforidis G, Avgeridis K, Sakellaropoulos G, Bassaris H, Maniatis A, Skoutelis A. Prevalence of hepatitis B and C virus infection in the general population and selected groups in South-Western Greece. Eur J Epidemiol 2003:18(6):551-557.
Sypsa V, Hadjjpaschali E, Hatzakis A. Prevalence, risk factors and evaluation of a screening strategy for chronic hepatitis B and C virus infection in healthy company employees.. Eur J Epidemiol 2001:17:721-728.
Goritsas C, Plerou I, Agaliotis C et al. HCV infection in the general population of a Gkeek island: prevalence and risk factors. Hepatogastorentelogy 2000:47:782-785.
Koulentaki M, Spanoudakis S, Kantidaki E et al. Prevalence of hepatitis B and C markers in volunteer blood donors in Crete: A 5- year study. J Viral Hepat 1999:6:243-248.
ZervouEK, Boumba DS, LiaskosCh et al. Low. Prevalence of HCV, HIV and HTLV-I/II infection markers in notthwestern Greece: results of a three year prospective donor stydy(1995-1997). Eur J Intern Med 2003:14:39-44.
Waslay A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000:20(1):1-16.
Bonkovsky H., WooleyJM and the Consensus Interferon Stydy Group. Reduction of health- related quality of life in chronic hepatitis C and im-provement with interferon therapy. Hepatology 1999:29(1):264-270.
Ware Jr J, Bayliss M, Mannocchia M., Davis G. and the International Hepatitis Interventional Therapy Group. Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response.. Hepatology 1999:30(2):550-555.
Manns MP. M Hutchioson JG, Gordon SC, RustgiVK, Shiffman M, Reindollar R et al. Pentinterferona2b plus ribavirin compared with interferon a2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001:358:958-965.
Fried MW, Shiffman ML, Reddy R, Smith C, Marinos G, Goncales F et al. Pentinterferona2b plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002:347:975-982.
Papatheodoridis GB, SklerosE. A. Annual Influenza of Hepatitis C Virus, Medicine 1994, 185-188.
Hadziyannis, S. et al. Peginterferon Alfa-2A(40KD) (PEGASYS) in Combination with Ribavirin (RBV): Efficacy and Safery Results from a Phase III, Randomized, Double-Blind, Multicentre Study Examining Effect of Duration of Treatment and RBV Dose. EASL, 2002.
Fried M. Peginterferon Alfa-2-a plus Rifavirin for Chronic Hepatitis C Infection NEJM 2002, 437(13) 975-982.
Bernstein, D. et al. Relationship of Health- Related Quality of life to Treatment Adherence and Sustained Response in Chronic Hepatitis C Patients. Hepatology:March 2002.
Bery C., Mc Murray J. A review of quality of life evaluations in patients with congestive heart failure. Pharmacoeconomics 1999;16:247 71.
Grady KL., Jaloviec A., White-Williams C., et al. Predictors of quality of life in patients with advanced heart failure awaiting transplantation. J. Heart, Lung Transplant. 1995;14:2-10.
Jaarsma T., Halfens R., Huijer Abu-Saad H., Dracup K., Stappers J., Van Ree J. Quality of life in older patients with systolic and diastolic heart failure. Eur Heart J. 1999;1:151-60.
Konstam V., Salem D., Pouleur H., et al. Baseline quality of life as a predictor of mortality and hospitalization in 5.025 patients with congestive heart failure. Am J Cardiol 1996;78:890-5.
Vaccario V., KaslSV., Abramson J., et al. Depressive symptoms and risk of functional decline and death in patients with heart failure. J Am Coll Cardiol 2001;38:199-05.
"Quality of Life" www.psnrenal.gr/periodiko/29/anemia/piotita.htm
Rigatos G. Cancer and quality of life. Greek Oncology.1993;29: 20.
Ware JE, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36), Conceptual framework and item selection. Med Care 1992;30:473-483.
Ware JE, Kosinski M, Keller SD. SF-36 physical and mental health summary scales: A user's manual. Boston MA: The Health Institute, Boston 1994.
Pappa E, Kontodimopoulos N, NiakasD. Psychometric evaluation and normative data for the Greek SF-36 health survey using a large urban population sample. Arch. Hel. Medicine 2006;23:159-166.
Perrillo R, Nair S. Hepatitis C. Zakim and Boyers Hepatology. A text-book of liver disease. TD Boyer, TLWright, MP Manns(eds). 5th Edition. Saunders Elsevier, Philadeiphia 2006;635-664.
Mourikis D., Hadjiioannou A. Vascular and Invasive Radiology. Ed. Beta. Athens, 2003.
Papatheodoridis G, Germanidis G, Dalek GN. Guidelines for therapeutic intervention in patients with hepatitis C virus infection. Hellenic Center for Disease Control & Prevention Working Group, Athens 2017.
Kitsanou M, Christodoulou KK, Katsanos KX, Kistis K, Familias I, Zervou E. And so on. Quality of Life and Hepatitis C: A Preliminary Study. 7th Workshop on Hepatitis C, Athens, 2000.
Gibson CM, Murphy SA, et al: Relationship of CK-MB release to thrombolysis in myocardial infarction perfusion grade after intracoronary stent placement: An ESPRIT substudy. Am Heart J 143: 106, 2002.
De Lemos JA, Morrow ΟΑ, et al: Early noninvasive detection of failed epicardialreperfasion after fibrinolytic therapy. Am J Cardiol.20012; 88:353.
Gomer K. Psychosocial risk factor profile in women with coronary heart disease. In Women, Stress and Heart Disease. Lawrence Erlbaum Associates, Inc., Publicers, London, 1998:25-38.
Mitchell AJ., Benito-León J., González JM., Rivera-Navarro J. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol. 2005;4(9):556-66.
Patti F., Russo P., Pappalardo A., Macchia F., Civalleri L., Paolillo A. Predictors of quality of life among patients with multiple sclerosis: an Italian cross-sectional study. J Neurol Sci. 2007;252(2):121-9.
Brink E, Brandsrtom Y, CliffoordssonCh et al. Illness Consequences after Myocardial infarction: problems with physical functioning and return to work. Jan Original Research. 2008 July 21:587-594.
Shah P, Najafi AH, Panza JA, Cooper HA. Outcomes and quality of life in patients> or =85 years of age with ST- elevation Myocardial infarction. AM J Cardiol. 2009;15:103(2):170-174.
Brink E, Grankvist G, Karlson BW, Hallberg LR. Health –related quality of lif women and men one year after acute Myocardial infarction. Qual Life Res. 2005;14(3): 749-757.
Suzuki S, Takaki H, Yasumura Y, et al. Assessment of quality of life 5 different scales in patients participating in comprehensive cardiac rehabilitation after acute Myocardial infarction. Circulation Journal 2005;69(12):1527-1534.
Rankin S, & Fukuoka Y. Predictors of Life in Women 1 year after Myocardial infarction. Progress in Cardiorascular Nurcing, Winter 2003.
Spilker B, Revicki DA. Taxonomy of quality of life. In Quality of Life and Pharmacoeconomics in Clinical Trials. Spilker B.(Ed). Philadelphia: Lippincott- Raven Publishers, 1996.
Lee DT, Yu DS, Woo J, Thompson DR. Health-related quality of life in patients with congestive heart failure. Eur J Heart Fail. 2005;7(3):419-22.
Clark DO, Tu W, Weiner M, Murray MD. Correlates of health-related quality of life among lower-income, urban adults with congestive heart failure. Heart Lung. 2003;32(6):391-401.
Souza E, Quadros A, Maestri R, et al. Predictors of Quality of Life Change after an Acute Coronary Event. Arq Bras Cardiol 2008: 91(4):229-235.
Piotrowicz R, Wolszakiewicz J. Cardiac rehabilitation following Myocardial infarction. Cardiol J. 2008;15(5):481-487.
Moser DK. The rust of life: impact of anxiety on cardiac patients. Am J Crit Care. 2007;16(4):361-9.
Koskinas J, Merkouraki P, Manesis E, Hadziyannis S. Assessment of depression in patients with chronic hepatitis: effect of interferon treatment. Dig Dis 2002;20:284-288.
Benito-León J, Morales JM, Rivera-Navarro J, Mitchell A. A review about the impact of multiple sclerosis on health-related quality of life. Disabil Rehabil. 2003;25(23):1291-303.
Ruo B, Summerfield JS, et al. Depressive Symptoms and Health- Related Quality of Life, JAMA, vol 290. 2003; 2:215-221.
Garavalia LS, Decker C, Reid KJ, Lichtman JH, et al. Does health status differ between men and women in early recovery after Myocardial infarction. Journal of Womens Health (Larchmt). 2007; 16(1):93-101.